Analysis of 129 Cases of Adverse Reactions and Clinical Application of Plasma Concentration Monitoring of Olanzapine

doi:10.19803/j.1672-8629.2020.11.15

Abstract

Abstract: Objective To analyze the adverse drug reactions (ADR) and plasma concentration monitoring of olanzapine so as to provide reference for clinical rational use of drugs. Methods A retrospective analysis of 129 cases of ADR by Shenzhen Kangning Hospital from January 2017 to June 2019 induced by olanzapine was conducted to explore the relationships between the patients' gender, age, dosage, drug combination, plasma concentration and concentration-dosage ratio (C/D) and ADR of olanzapine. Results ADR mainly damaged the neuropsychiatric system, hepatobiliary system and cardiovascular system. The most common clinical manifestations were abnormal liver function, extrapyramidal diseases and akathisia. Most of the patients were aged 19 to 40. ADR reports involved more females than males, but in reports of serious ADR, males outnumbered females(P <0.05). There was no significant difference in the incidence of serious ADR between combined medication and single medication(P>0.05). 72.87% of the patients had their plasma concentrations monitored during the occurrence of ADR. There was no significant difference in the plasma concentration or C/D value between ADR and serious ADR(P>0.05). Conclusion When olanzapine is used in clinic, clinicians should strengthen the monitoring of ADR and therapeutic drugs, reduce drug combination, and ensure the safety of clinical drug use.

Key words: olanzapine, adverse drug reactions, plasma concentration, drug combination

CLC Number:

R994.11

ZENG Huansi, ZHONG Caini, ZHONG Yilin, PENG Chenchen, ZHANG Xuan. Analysis of 129 Cases of Adverse Reactions and Clinical Application of Plasma Concentration Monitoring of Olanzapine[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 818-822.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2020.11.15

https://zgywjj.magtechjournal.com/EN/Y2020/V17/I11/818

References

[1] Rojo LE, Gaspar PA, Silva H, et al.Metabolic Syndrome and Obesity among Users of Second Generation Antipsychotics: A Global Challenge for Modern Psychopharmacology[J]. Pharmacological Research, 2015, 101(11): 74-85.
[2] Zhang DL, Lu L, Yao P, et al.Analysis of 183 Cases of Adverse Drug Reactions Induced by Atypical Antipsychotropic Drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(2): 109-112.
[3] Barak N, Beck Y, Albeck JH.A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain[J]. Journal of Clinical Psychopharmacology, 2016, 36(3): 253-256.
[4] Hiemke C, Bergemann N, Clement H, et al.Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017[J]. Pharmacopsychiatry, 2018, 51(1/2): 9-62.
[5] Ministry of Health of the People's Republic of China. Provisions for Adverse Drug Reaction Reporting and Monitoring(Order No. 81 of the Ministry of Health)[EB/OL]. (2011-05-04) [2018-10-28]. http://www.gov.cn/flfg/2011-05/24/content_1870110.htm.
[6] Zeng H S, Zhang X, Zhong CN, et al.Utilization of Antipsychotic Drugs in Our Hospital from 2012 to 2014[J]. China Pharmaceuticals(中国药业), 2016, 25(9): 73-76.
[7] Deng C.Effects of antipsychotic medications on appetite, weight, and insulin resistance[J]. Endocrinology and Metabolism Clinics, 2013, 42(3): 545-563.
[8] Song ME, Lu HY, Wang ZZ, et al.Retrospective Analysis of 302 Cases of Adverse Drug Reactions Induced by Olanzapine[J]. Pharmacy Today(今日药学), 2017, 27(5): 345-348.
[9] Ni W, Zhou HP, Huang ST, et al.Research Progress of Atypical Antipsychotic[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2009, 29(18): 1570-1573.
[10] Detke HC, Weiden PJ, Llorca PM, et al.Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia[J]. Journal of Clinical Psychopharmacology, 2014, 34(4): 426-434.
[11] Wang J, Su MJ, Zhao XY, et al.Retrospective Analysis on 365 Cases of Adverse Drug Reactions in a Psychiatric Hospital[J]. Chinese Journal of pharmacovigilance(中国药物警戒), 2015, 12(9): 560-563.
[12] Telles-Correia D, Barbosa A, Cortez-Pinto H, et al.Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity[J]. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2017, 8(1): 26.
[13] Xia L, Li WZ, Liu HZ, et al.Olanzapine versus risperidone in children and adolescents with psychosis: a meta-analysis of randomized controlled trials[J]. Journal of Child and Adolescent Psychopharmacology, 2018, 28(4): 244-251.
[14] Sun ZX, Yu XF.Progress in studies on tardive dystonia induced by antipsychotic drugs[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2012, 14(1): 34-35.
[15] Hao JY, Chen BH, Qin TX, et al.Clinical Observation of Ziprasidone Combined with Olanzapine in the Treatment of Refractory Schizophre-nia in Elderly Patients[J]. China Pharmacy(中国药房), 2015, 26(33): 4652-4654.
[16] Zhou QJ, Wu XY, Qu FL.A case of measles-like drug eruption caused by olanzapine[J]. Chinese Journal of pharmacovigilance(中国药物警戒), 2012, 9(10): 639-640.
[17] Woon LS-C, Tee CK, Gan LLY, et al.Olanzapine-induced and risper-idone-induced leukopenia: a case of synergistic adverse reaction[J]. Journal of Psychiatric Practice®, 2018, 24(2): 121-124.